AlphaQuest LLC Purchases 1,826 Shares of Haemonetics Co. (NYSE:HAE)

AlphaQuest LLC increased its position in Haemonetics Co. (NYSE:HAE) by 36,520.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,831 shares of the medical instruments supplier’s stock after acquiring an additional 1,826 shares during the period. AlphaQuest LLC’s holdings in Haemonetics were worth $143,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Global Alpha Capital Management Ltd. grew its holdings in Haemonetics by 70.6% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 17,101 shares of the medical instruments supplier’s stock valued at $1,335,000 after purchasing an additional 7,076 shares during the period. AMG National Trust Bank bought a new stake in Haemonetics during the fourth quarter valued at about $746,000. Ashton Thomas Private Wealth LLC bought a new stake in Haemonetics during the fourth quarter valued at about $284,000. Raymond James Financial Inc. bought a new stake in Haemonetics during the fourth quarter valued at about $19,002,000. Finally, Arizona State Retirement System grew its holdings in Haemonetics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock valued at $1,160,000 after purchasing an additional 181 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 1.0 %

Haemonetics stock opened at $64.84 on Tuesday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The business has a fifty day moving average price of $68.33 and a 200-day moving average price of $75.34.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HAE has been the subject of several recent research reports. Barrington Research cut their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Needham & Company LLC lowered their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. Finally, Raymond James restated a “strong-buy” rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and an average price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.